vs

Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and WESTPORT FUEL SYSTEMS INC. (WPRT). Click either name above to swap in a different company.

WESTPORT FUEL SYSTEMS INC. is the larger business by last-quarter revenue ($12.5M vs $9.1M, roughly 1.4× Protalix BioTherapeutics, Inc.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -274.8%, a 214.5% gap on every dollar of revenue. On growth, WESTPORT FUEL SYSTEMS INC. posted the faster year-over-year revenue change (-11.4% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-6.4M).

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

Westport Innovations is a company that develops alternative fuel, low-emissions technologies to allow engines to operate on clean-burning fuels such as compressed natural gas (CNG), liquefied natural gas (LNG), hydrogen and biofuels such as landfill gas. Headquartered in Vancouver, British Columbia, Canada, where the company was founded, Westport also has facilities in France, Sweden, Italy, China, Australia and the United States.

PLX vs WPRT — Head-to-Head

Bigger by revenue
WPRT
WPRT
1.4× larger
WPRT
$12.5M
$9.1M
PLX
Growing faster (revenue YoY)
WPRT
WPRT
+38.5% gap
WPRT
-11.4%
-49.9%
PLX
Higher net margin
PLX
PLX
214.5% more per $
PLX
-60.3%
-274.8%
WPRT
More free cash flow
PLX
PLX
$8.1M more FCF
PLX
$1.6M
$-6.4M
WPRT

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
PLX
PLX
WPRT
WPRT
Revenue
$9.1M
$12.5M
Net Profit
$-5.5M
$-34.3M
Gross Margin
49.4%
6.7%
Operating Margin
-51.1%
-8.1%
Net Margin
-60.3%
-274.8%
Revenue YoY
-49.9%
-11.4%
Net Profit YoY
-184.8%
-690.4%
EPS (diluted)
$-0.06
$-1.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PLX
PLX
WPRT
WPRT
Q4 25
$9.1M
Q3 25
$17.9M
Q2 25
$15.7M
$12.5M
Q1 25
$10.1M
Q4 24
$18.2M
Q3 24
$18.0M
$4.9M
Q2 24
$13.5M
$14.1M
Q4 23
$10.5M
Net Profit
PLX
PLX
WPRT
WPRT
Q4 25
$-5.5M
Q3 25
$2.4M
Q2 25
$164.0K
$-34.3M
Q1 25
$-3.6M
Q4 24
$6.5M
Q3 24
$3.2M
$-3.9M
Q2 24
$-2.2M
$5.8M
Q4 23
$-6.0M
Gross Margin
PLX
PLX
WPRT
WPRT
Q4 25
49.4%
Q3 25
53.4%
Q2 25
62.5%
6.7%
Q1 25
19.1%
Q4 24
78.7%
Q3 24
53.4%
13.6%
Q2 24
29.8%
16.7%
Q4 23
15.5%
Operating Margin
PLX
PLX
WPRT
WPRT
Q4 25
-51.1%
Q3 25
11.9%
Q2 25
7.5%
-8.1%
Q1 25
-41.0%
Q4 24
39.6%
Q3 24
22.2%
-43.9%
Q2 24
-18.0%
-54.9%
Q4 23
-53.5%
Net Margin
PLX
PLX
WPRT
WPRT
Q4 25
-60.3%
Q3 25
13.2%
Q2 25
1.0%
-274.8%
Q1 25
-35.8%
Q4 24
35.6%
Q3 24
18.0%
-79.3%
Q2 24
-16.4%
41.2%
Q4 23
-57.6%
EPS (diluted)
PLX
PLX
WPRT
WPRT
Q4 25
$-0.06
Q3 25
$0.03
Q2 25
$0.00
$-1.98
Q1 25
$-0.05
Q4 24
$0.10
Q3 24
$0.03
$-0.22
Q2 24
$-0.03
$0.34
Q4 23
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PLX
PLX
WPRT
WPRT
Cash + ST InvestmentsLiquidity on hand
$14.7M
$6.1M
Total DebtLower is stronger
$977.0K
Stockholders' EquityBook value
$48.2M
$108.9M
Total Assets
$82.3M
$272.1M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PLX
PLX
WPRT
WPRT
Q4 25
$14.7M
Q3 25
$13.6M
Q2 25
$17.9M
$6.1M
Q1 25
$19.5M
Q4 24
$19.8M
Q3 24
$27.4M
Q2 24
$23.4M
Q4 23
$23.6M
Total Debt
PLX
PLX
WPRT
WPRT
Q4 25
Q3 25
Q2 25
$977.0K
Q1 25
Q4 24
Q3 24
Q2 24
Q4 23
Stockholders' Equity
PLX
PLX
WPRT
WPRT
Q4 25
$48.2M
Q3 25
$52.9M
Q2 25
$49.9M
$108.9M
Q1 25
$45.2M
Q4 24
$43.2M
Q3 24
$32.4M
$149.3M
Q2 24
$28.6M
$151.5M
Q4 23
$33.6M
Total Assets
PLX
PLX
WPRT
WPRT
Q4 25
$82.3M
Q3 25
$82.3M
Q2 25
$78.5M
$272.1M
Q1 25
$73.9M
Q4 24
$73.4M
Q3 24
$61.6M
Q2 24
$91.5M
Q4 23
$84.4M
Debt / Equity
PLX
PLX
WPRT
WPRT
Q4 25
Q3 25
Q2 25
0.01×
Q1 25
Q4 24
Q3 24
Q2 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PLX
PLX
WPRT
WPRT
Operating Cash FlowLast quarter
$2.0M
$-5.6M
Free Cash FlowOCF − Capex
$1.6M
$-6.4M
FCF MarginFCF / Revenue
17.8%
-51.6%
Capex IntensityCapex / Revenue
4.4%
6.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-13.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PLX
PLX
WPRT
WPRT
Q4 25
$2.0M
Q3 25
$-3.7M
Q2 25
$-5.2M
$-5.6M
Q1 25
$-5.1M
Q4 24
$4.0M
Q3 24
$4.1M
$-11.7M
Q2 24
$-3.6M
$1.5M
Q4 23
$3.6M
Free Cash Flow
PLX
PLX
WPRT
WPRT
Q4 25
$1.6M
Q3 25
$-4.2M
Q2 25
$-5.7M
$-6.4M
Q1 25
$-5.4M
Q4 24
$3.6M
Q3 24
$4.0M
$-11.9M
Q2 24
$-3.8M
$262.0K
Q4 23
$3.3M
FCF Margin
PLX
PLX
WPRT
WPRT
Q4 25
17.8%
Q3 25
-23.7%
Q2 25
-36.2%
-51.6%
Q1 25
-53.0%
Q4 24
19.6%
Q3 24
22.4%
-243.4%
Q2 24
-28.1%
1.9%
Q4 23
31.9%
Capex Intensity
PLX
PLX
WPRT
WPRT
Q4 25
4.4%
Q3 25
2.8%
Q2 25
2.8%
6.6%
Q1 25
3.0%
Q4 24
2.3%
Q3 24
0.5%
3.8%
Q2 24
1.3%
8.9%
Q4 23
2.4%
Cash Conversion
PLX
PLX
WPRT
WPRT
Q4 25
Q3 25
-1.58×
Q2 25
-31.91×
Q1 25
Q4 24
0.61×
Q3 24
1.27×
Q2 24
0.26×
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PLX
PLX

Products$8.7M95%
Other$428.0K5%

WPRT
WPRT

Segment breakdown not available.

Related Comparisons